Good MorningEquity markets did an about-face on Wednesday, rising in early trading and then falling after the FOMC announced more interest rate hikes were coming. The FOMC paused in June, holding rates steady, but indicated inflation was not tamed and that 2 more should be expected. The news sent the odds on the CME's FedWatch Tool rocketing higher, indicating a significant outlook shift. The takeaway is that interest rate cuts should not be expected in 2023 without a significant decline in inflation.
Action in the S&P 500 was mixed. The index moved up, down, and sideways during the session while market participants digested the news. The implications for stocks are negative; rising rates are cutting into demand, which is capping the outlook for earnings. The market closed with a small gain for the day, creating a large Doji candle signifying significant uncertainty. The market may move higher from here, but it is climbing a wall of worry and heading toward a ceiling put in place by the Fed. Featured: U.S. Loses to China in Shocking WAR GAMES (Behind the Markets) 
|
Stocks | | |
When you hear about stocks in the news, they often refer to an event that drives share prices up or down. Fundamental analysis interprets the news and the performance of a company's operations to derive a value for the underlying stock. However, all stocks must contend with an underlying pric... Read the Full Story |
|
From Our PartnersGraphite has emerged as a vital material in the resource sector, gaining prominence primarily due to its essential role in electric vehicle (EV) batteries.
We found a little-known graphite company exploring the potential of this mineral and is currently flying under Wall Street's radar.
This company's operations are positioning them as a leader in a critical industry with growing demand.
| | Click here for the free report that reveals the ticker symbol! |
|
Stocks | | |
The global economic landscape has been in flux since the start of 2020, with markets worldwide experiencing both highs and lows in the wake of the global COVID-19 pandemic, the ongoing war in Ukraine and countless other factors.
Some investors have managed to profit from these wild swings. ... Read the Full Story |
|
Markets | | | Asian shares logged moderate gains on Friday after Wall Street benchmarks swept higher, extending their longest rally in a year and a half. The Bank of Japan wrapped up a policy meeting by keeping its ultra-lax monetary stance unchanged, as expected. It is a standout among central banks, most of whi... Read the Full Story |
|
From Our PartnersSkyrocketing national debt, persistent inflationary pressures, and a government struggling to implement effective measures all serve as clear signals of an impending collapse. The implications of such an event would be nothing short of catastrophic.
By clicking link you are subscribing to The Darwin Investor Network and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.
| | Click here to download the free report |
|
Markets | | | After more than two decades as America’s best-selling beer, Bud Light has slipped into second place.Modelo Especial, a Mexican lager, overtook Bud Light in U.S. retail dollar sales in the month ending June 3, according to Nielsen data analyzed by Bump Williams Consulting. Modelo controlled 8.4% of U... Read the Full Story |
|
Markets | | |
Advanced Micro Devices (NASDAQ: AMD) announced game-changing news when unveiled the MI300X super chip. The MI300X is the company’s latest development and a pure play on AI. The chip is intended to rival NVIDIA (NASDAQ: NVDA) chips, such as the H100, which run for around $30,000 each. That&rs... Read the Full Story |
|
From Our PartnersLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain. | | See why "Made in America" graphite should be on every investor's radar |
|
Markets | | | The European Central Bank pressed ahead with another interest rate hike Thursday and made clear more are on the way, aiming to crush inflation that is driving up the cost of groceries even after the U.S. Federal Reserve took a break from its own string of increases.The quarter-point rate boost, to 3... Read the Full Story |
|
Markets | | | New Zealand's economy has dipped into recession as higher interest rates take their toll, new figures released Thursday show.Gross domestic product fell by 0.1% in the March quarter, following a revised 0.7% fall in the previous quarter, Statistics New Zealand said. That fulfils the nation's definit... Read the Full Story |
|
Markets | | | The Federal Reserve’s decision Wednesday to leave interest rates alone for the first time in 11 meetings raises hopes that it may be at least nearing the end of its rate-hiking campaign to cool inflation.That said, the Fed's policymakers indicated that they envision potentially two more hikes this y... Read the Full Story |
|
Markets | | |
On Monday, Chegg (NYSE: CHGG) announced that it is laying off 4% of its workforce and parlaying the cost savings into executing its AI strategy. Chegg has been one of the headline "AI losers," or companies that see their business model under threat due to the rise of AI chatbots like ChatGPT. The ... Read the Full Story |
|
Markets | | |
Shares of Mullen Automotive (NASDAQ: MULN) are down another 15% to trade back at the pre-split level near $.25. That’s a bitter pill to swallow for investors holding out hopes this company can defy the odds and pull off production, sales, revenue, and earnings. There are many reasons to hope... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. | | View Today's Stock Pick |
|
